12:00 AM
 | 
Apr 05, 2010
 |  BC Week In Review  |  Company News  |  Other News

Medivation neurology, cancer news

Medivation reduced headcount by 23 (20%) to 88 a month after the company's Dimebon latrepirdine missed the co-primary endpoints in a...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >